This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Netflix, AstraZeneca & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), AstraZeneca (AZN) and Union Pacific (UNP).
AstraZeneca's Farxiga Gets Fast Track Tag for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.
Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More
by Kinjel Shah
J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.
J&J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $57.43 in the latest trading session, marking a -0.98% move from the prior day.
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
by Zacks Equity Research
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
AstraZeneca (AZN) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Q2 Earnings in Focus
by Zacks Equity Research
Q2 Earnings in Focus
Goldman Boosts Dow with Best Quarter in Years
by Mark Vickery
Goldman simply blew the doors off Q2 expectations, posting $6.26 per share on $13.3 billion in quarterly revenues which compare very favorably with the $3.97 per share and $10.07 billion in the Zacks consensus.
J&J's Tremfya Receives FDA Approval for Psoriatic Arthritis
by Zacks Equity Research
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis receives approval in the United States.
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
Immunomedics Extends Deal With Roche for Two New Studies
by Zacks Equity Research
Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.
Pfizer/BioNTech's Coronavirus Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
Pfizer's (PFE) shares jump after FDA grants fast track status to two coronavirus vaccine candidates
Is AstraZeneca (AZN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AZN) Outperforming Other Medical Stocks This Year?
Roche's (RHHBY) Tecentriq Disappoints in Ovarian Cancer Study
by Zacks Equity Research
Roche's (RHHBY) phase III study on Tecentriq in combination with Avastin fails to meet its primary goal.
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
by Zacks Equity Research
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
Moderna Collaborates to Support Coronavirus Vaccine Supply
by Zacks Equity Research
Moderna (MRNA) signs manufacturing deal with Europe-based pharma company, Rovi, to support supply of its coronavirus vaccine in ex-US markets.
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
by Kinjel Shah
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
Astrazeneca (AZN) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $53.97 in the latest trading session, marking a -0.41% move from the prior day.
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
by Zacks Equity Research
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
AstraZeneca's sNDA for Brilinta Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts AstraZeneca's (AZN) sNDA for Brilinta under a Priority Review to lower subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.
Moderna Completes Enrollment in Phase II Coronavirus Study
by Zacks Equity Research
Moderna (MRNA) is progressing well with its coronavirus vaccine development. It completes enrollment in a phase II study and finalizes phase III study protocol.
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.
Corvus Starts Immunotherapy Study on Coronavirus, Stock Rises
by Zacks Equity Research
Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.